A Multicenter, Randomized, Double-Blind Study Comparing The Efficacy And Safety Of Aflibercept Versus Placebo Administered Every 3 Weeks In Patients Treated With Docetaxel / Prednisone For Metastatic Androgen-Independent Prostate Cancer.

Trial Profile

A Multicenter, Randomized, Double-Blind Study Comparing The Efficacy And Safety Of Aflibercept Versus Placebo Administered Every 3 Weeks In Patients Treated With Docetaxel / Prednisone For Metastatic Androgen-Independent Prostate Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Aflibercept (Primary) ; Docetaxel; Prednisolone; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VENICE
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2017 Results of longitudinal pain score data from three phase III studies including this study presented at the 112th Annual Meeting of the American Urological Association
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top